The acquisition includes dsm-firmenich’s Marine Lipids omega-3 fish oil business for the food and beverage, dietary supplement and pharmaceutical markets, as well as the MEG-3® brand and production facilities in Piura, Peru and Mulgrave, Canada. In return, dsm-firmenich has received a minority stake in the enlarged KD group.
Oscar Groet, CEO of KD Pharma Group, said: “This is a historic day for our company. We are excited about the new opportunities that lie ahead of us, which will allow us to better advance our mission of creating innovative health solutions that help people live better lives. We now have a leadership position throughout the value chain from refined oils to pharmaceutical APIs to softgel capsule manufacturing. We are committed to ensuring that our customers from both businesses have a seamless experience as we integrate the acquisition and promise they will receive the highest levels of service and market-leading quality.”
With approximately 710 employees, the expanded KD Pharma Group now has seven manufacturing facilities in the UK, Norway, Germany, Canada, Peru and the US, and benefits from a wider range of products and customization capabilities.
